Barclays Maintains Overweight on Insmed, Raises Price Target to $63
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Leon Wang maintains an Overweight rating on Insmed (NASDAQ:INSM) and raises the price target from $40 to $63.
May 29, 2024 | 12:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays analyst Leon Wang maintains an Overweight rating on Insmed and raises the price target from $40 to $63.
The raised price target from $40 to $63 by Barclays, along with the maintained Overweight rating, indicates strong confidence in Insmed's future performance. This is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100